论文部分内容阅读
目的观察5-Fu小剂量泵二线治疗晚期胰腺癌的疗效和不良反应。方法 13例晚期吉西他滨治疗失败的胰腺癌患者,5-Fu300mg/d,1～14d持续静脉泵入,DDP5mg1～5d,8～12d静点,28d为1周期。观察客观疗效、临床获益率及不良反应。结果部分缓解1例,稳定6例,10例临床获益,中位生存期5.8个月(2.2～8.3个月),中位疾病进展时间3.0个月(1～4.5个月),主要不良反应为菌群失调相关性腹泻。结论 5-Fu小剂量泵二线治疗可改善晚期胰腺癌患者生存,耐受性好。
Objective To observe the efficacy and adverse reactions of second-line 5-Fu low-dose pump in the treatment of advanced pancreatic cancer. Methods 13 patients with advanced pancreatic cancer treated with gemcitabine failed, 5-Fu 300mg/d, 1 ~ 14d continuous intravenous pumping, DDP 5mg 1 ~ 5d, 8 ~ 12d static, 28d 1 cycle. Observe the objective efficacy, clinical benefit rate and adverse reactions. Results Partial remission in 1 case, stable in 6 cases, clinical benefit in 10 cases, median survival period 5.8 months (2.2 to 8.3 months), median disease progression time 3.0 months (1 to 4.5 months), major adverse reactions For dysbacteriosis-associated diarrhea. Conclusion The second-line treatment of 5-Fu low-dose pump can improve the survival of patients with advanced pancreatic cancer and is well tolerated.